CBS 2019
CBSMD教育中心
中 文

科学研究

Abstract

Recommended Article

Aggressive lipid-lowering therapy after percutaneous coronary intervention – for whom and how? AIM2-driven inflammasome activation in heart failure Disrupting Fellow Education Through Group Texting: WhatsApp in Fellow Education? Screening for Atrial Fibrillation With Electrocardiography US Preventive Services Task Force Recommendation Statement Coronary Angiography after Cardiac Arrest — The Right Timing or the Right Patients? Alirocumab Reduces Total Nonfatal Cardiovascular and Fatal Events in the ODYSSEY OUTCOMES Trial Healthy Behavior, Risk Factor Control, and Survival in the COURAGE Trial Optimal medical therapy improves clinical outcomes in patients undergoing revascularization with percutaneous coronary intervention or coronary artery bypass grafting: insights from the Synergy Between Percutaneous Coronary Intervention with TAXUS and Cardiac Surgery (SYNTAX) trial at the 5-year follow-up

Original Research2021 Jun 12;cvab202.

JOURNAL:Cardiovasc Res. Article Link

AIM2-driven inflammasome activation in heart failure

Z Onódi, M Ruppert, D Kucsera et al. Keywords: canakinumab; cardiomyopathy; drug repurposing; heart failure; inflammation; probenecid

Full Text PDF